TrialTargeted oncology2023

Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.

Chao-Hua Chiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.